转化形态学与至灭绝时间分析:将结核病临床前模型的治疗时长映射至患者
该研究利用集合论映射建立计算建模框架,将多个中空纤维系统结核模型(HFS-TB)中化疗杀灭结核分枝杆菌所需时间映射至患者观察数据。利用108个HFS-TB REMoxTB单元(含756 CFU/mL)数据测试转化预测准确性,并预测4个月和6个月治疗后治愈与复发,与REMoxTB临床试验中1932例患者观察结果比较。HFS-TB数据准确预测了4个月REMoxTB试验中治愈患者比例。
要点
- 建立从临床前模型到患者的治疗时长转化映射方法
- HFS-TB数据准确预测4个月REMoxTB试验治愈比例
- 为抗结核治疗时长转化提供计算建模框架
核心结论
- 开发了一种将临床前模型治疗时长结果转化至结核患者的方法。
研究设计与样本
- 使用集合论映射建立计算建模框架,将多个HFS-TB实验中杀灭结核分枝杆菌所需时间映射至患者观察数据。
- 利用108个HFS-TB REMoxTB单元(包括756 CFU/mL)数据测试转化预测准确性。
- 采用拉丁超立方抽样引导的模拟预测4个月和6个月治疗后的治愈与复发,并与REMoxTB临床试验中1932例患者观察结果比较。
主要发现
- HFS-TB连续细菌负荷与 derivation 数据集中连续痰数据形成结构保持映射。
- 杀菌效应通过单步转化映射,灭菌效应通过三步转化函数映射。
- 使用HFS-TB REMoxTB数据准确预测了4个月REMoxTB临床试验中治愈患者比例。
- 模型预测 vs 临床试验观察:乙胺丁醇组 77.0% [95%CI 74.4%-79.6%] vs 77.7% [95%CI 74.3%-80.9%]。
- 模型预测 vs 临床试验观察:异烟肼组 76.4% [95%CI 73.9%-79.0%] vs 79.5% [95%CI 76.1%-82.5%]。
临床怎么用
- 该转化方法可用于将临床前模型中的治疗时长结果映射至结核患者,辅助治疗时长决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A major challenge in medicine is translation of preclinical model findings to humans, especially therapy duration. One major example is recent shorter-duration therapy regimen failures in tuberculosis. METHODS: We used set theory mapping to develop a computational/modeling framework to map the time it takes to extinguish the Mycobacterium tuberculosis population on chemotherapy from multiple hollow fiber system model of tuberculosis (HFS-TB) experiments to that observed in patients. The predictive accuracy of the derived translation transformations was then tested using data from 108 HFS-TB Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) units, including 756 colony-forming units (CFU)/mL. Derived transformations, and Latin hypercube sampling-guided simulations were used to predict cure and relapse after 4 and 6 months of therapy. Outcomes were compared to observations, in 1932 patients in the REMoxTB clinical trial. RESULTS: HFS-TB serial bacillary burden and serial sputum data in the derivation dataset formed a structure-preserving map. Bactericidal effect was mapped with a single step transformation, while the sterilizing effect was mapped with a 3-step transformation function. Using the HFS-TB REMoxTB data, we accurately predicted the proportion of patients cured in the 4-month REMoxTB clinical trial. Model-predicted vs clinical trial observations were (i) the ethambutol arm (77.0% [95% confidence interval {CI}, 74.4%-79.6%] vs 77.7% [95% CI, 74.3%-80.9%]) and (ii) the isoniazid arm (76.4% [95% CI, 73.9%-79.0%] vs 79.5% [95% CI, 76.1%-82.5%]). CONCLUSIONS: We developed a method to translate duration of therapy outcomes from preclinical models to tuberculosis patients.
引用
- Magombedze G, Pasipanodya JG, Srivastava S, et al. Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. Clin Infect Dis. 2018. PMID: 30496464. doi:10.1093/cid/ciy623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。